Posted by Michael Wonder on 18 Oct 2021
Novartis applauds Quebec, the first province to list Zolgensma for the treatment of paediatric patients with spinal muscular atrophy
15 October 2021 - Public reimbursement under the Régie de l'assurance maladie du Québec, effective October 20th will apply for children with SMA following the recommendation from the Institut national d'excellence en santé et services sociaux.
Novartis Pharmaceuticals Canada applauds the government of Quebec's decision to provide public reimbursement for Zolgensma (onasemnogene abeparvovec) under the Régie de l'assurance maladie du Québec for the treatment of children with SMA.
